Skip to main content
SpringerLink
Log in

Translocation Testing of Lung Cancer Biomarkers

  • Chapter
  • First Online:
Precision Molecular Pathology of Lung Cancer

Part of the book series: Molecular Pathology Library ((MPLB))

  • 1441 Accesses

Abstract

Detection of gene rearrangements has evolved from classical cytogenetic karyotyping through CGH/aCGH to FISH and RT-PCR. Gene rearrangements cause fusion protein overexpression, and immunohistochemistry (IHC) has been increasingly used as a surrogate method for detection of gene rearrangements. Recently several next-generation sequencing platforms for detection of gene fusions have been developed and implemented into clinical practice. Gene rearrangements have been successfully identified with both FISH and IHC in isolated circulating tumor cells (CTCs). CTCs and cell-free tumor DNA (cfDNA) will most likely be used in clinical practice for detection of rearrangements. This chapter will mainly focus on ALK FISH and RT-PCR assays as an example for translocation testing in lung cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 44.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 59.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med. 2013;137(6):828–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561–6.

    Article  CAS  PubMed  Google Scholar 

  3. Takeuchi K, Choi YL, Togashi Y, Soda M, Hatano S, Inamura K, et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res. 2009;15(9):3143–9.

    Article  CAS  PubMed  Google Scholar 

  4. Togashi Y, Soda M, Sakata S, Sugawara E, Hatano S, Asaka R, et al. KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only. PLoS One. 2012;7(2):e31323.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363(18):1693–703.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Camidge DR, Theodoro M, Maxson DA, Skokan M, O’Brien T, Lu X, et al. Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cancer. Cancer. 2012;118(18):4486–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Conde E, Suarez-Gauthier A, Benito A, Garrido P, Garcia-Campelo R, Biscuola M, et al. Accurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry. PLoS One. 2014;9(9):e107200.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Cutz JC, Craddock KJ, Torlakovic E, Brandao G, Carter RF, Bigras G, et al. Canadian anaplastic lymphoma kinase study: a model for multicenter standardization and optimization of ALK testing in lung cancer. J Thorac Oncol. 2014;9(9):1255–63.

    Article  CAS  PubMed  Google Scholar 

  9. Djalalov S, Beca J, Hoch JS, Krahn M, Tsao MS, Cutz JC, et al. Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer. J Clin Oncol. 2014;32(10):1012–9.

    Article  PubMed  Google Scholar 

  10. Shan L, Jiang P, Xu F, Zhang W, Guo L, Wu J, et al. BIRC6-ALK, a novel fusion gene in ALK break-apart FISH-negative lung adenocarcinoma responds to crizotinib. J Thorac Oncol. 2015;10(6):e37–9.

    Article  PubMed  Google Scholar 

  11. Li W, Zhang J, Guo L, Chuai S, Shan L, Ying J. Combinational analysis of FISH and immunohistochemistry reveals rare genomic events in ALK fusion patterns in NSCLC that responds to crizotinib treatment. J Thorac Oncol. 2017;12(1):94–101.

    Article  PubMed  Google Scholar 

  12. Gao X, Sholl LM, Nishino M, Heng JC, Janne PA, Oxnard GR. Clinical implications of variant ALK FISH rearrangement patterns. J Thorac Oncol. 2015;10(11):1648–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Dacic S, Villaruz LC, Abberbock S, Mahaffey A, Incharoen P, Nikiforova MN. ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma. Oncotarget. 2016;7(50):82943–52.

    PubMed  PubMed Central  Google Scholar 

  14. Takeuchi K, Togashi Y, Kamihara Y, Fukuyama T, Yoshioka H, Inoue A, et al. Prospective and clinical validation of ALK immunohistochemistry: results from the phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study). Ann Oncol. 2016;27(1):185–92.

    Article  CAS  PubMed  Google Scholar 

  15. Lira ME, Kim TM, Huang D, Deng S, Koh Y, Jang B, et al. Multiplexed gene expression and fusion transcript analysis to detect ALK fusions in lung cancer. J Mol Diagn. 2013;15(1):51–61.

    Article  CAS  PubMed  Google Scholar 

  16. McLeer-Florin A, Moro-Sibilot D, Melis A, Salameire D, Lefebvre C, Ceccaldi F, et al. Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study. J Thorac Oncol. 2012;7(2):348–54.

    Article  PubMed  Google Scholar 

  17. Pekar-Zlotin M, Hirsch FR, Soussan-Gutman L, Ilouze M, Dvir A, Boyle T, et al. Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer. Oncologist. 2015;20(3):316–22.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Peled N, Palmer G, Hirsch FR, Wynes MW, Ilouze M, Varella-Garcia M, et al. Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer. J Thorac Oncol. 2012;7(9):e14–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Sholl LM, Weremowicz S, Gray SW, Wong KK, Chirieac LR, Lindeman NI, et al. Combined use of ALK immunohistochemistry and FISH for optimal detection of ALK-rearranged lung adenocarcinomas. J Thorac Oncol. 2013;8(3):322–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Weickhardt AJ, Aisner DL, Franklin WA, Varella-Garcia M, Doebele RC, Camidge DR. Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancer. Cancer. 2013;119(8):1467–77.

    Article  CAS  PubMed  Google Scholar 

  21. Ali SM, Hensing T, Schrock AB, Allen J, Sanford E, Gowen K, et al. Comprehensive genomic profiling identifies a subset of crizotinib-responsive ALK-rearranged non-small cell lung cancer not detected by fluorescence in situ hybridization. Oncologist. 2016;21(6):762–70.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Jang JS, Wang X, Vedell PT, Wen J, Zhang J, Ellison DW, et al. Custom gene capture and next-generation sequencing to resolve discordant ALK status by FISH and IHC in lung adenocarcinoma. J Thorac Oncol. 2016;11(11):1891–900.

    Article  PubMed  Google Scholar 

  23. Wiesner T, Lee W, Obenauf AC, Ran L, Murali R, Zhang QF, et al. Alternative transcription initiation leads to expression of a novel ALK isoform in cancer. Nature. 2015;526(7573):453–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Soda M, Isobe K, Inoue A, Maemondo M, Oizumi S, Fujita Y, et al. A prospective PCR-based screening for the EML4-ALK oncogene in non-small cell lung cancer. Clin Cancer Res. 2012;18(20):5682–9.

    Article  CAS  PubMed  Google Scholar 

  25. Choi YL, Takeuchi K, Soda M, Inamura K, Togashi Y, Hatano S, et al. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res. 2008;68(13):4971–6.

    Article  CAS  PubMed  Google Scholar 

  26. Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano S, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med. 2012;18(3):378–81.

    Article  CAS  PubMed  Google Scholar 

  27. Rimkunas VM, Crosby KE, Li D, Hu Y, Kelly ME, Gu TL, et al. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion. Clin Cancer Res. 2012;18(16):4449–57.

    Article  CAS  PubMed  Google Scholar 

  28. Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012;30(8):863–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Tsuta K, Kohno T, Yoshida A, Shimada Y, Asamura H, Furuta K, et al. RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis. Br J Cancer. 2014;110(6):1571–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Sasaki H, Shimizu S, Tani Y, Maekawa M, Okuda K, Yokota K, et al. RET expression and detection of KIF5B/RET gene rearrangements in Japanese lung cancer. Cancer Med. 2012;1(1):68–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Kohno T, Ichikawa H, Totoki Y, Yasuda K, Hiramoto M, Nammo T, et al. KIF5B-RET fusions in lung adenocarcinoma. Nat Med. 2012;18(3):375–7.

    Article  CAS  PubMed  Google Scholar 

  32. Dacic S, Luvison A, Evdokimova V, Kelly L, Siegfried JM, Villaruz LC, et al. RET rearrangements in lung adenocarcinoma and radiation. J Thorac Oncol. 2014;9(1):118–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Wang R, Hu H, Pan Y, Li Y, Ye T, Li C, et al. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. J Clin Oncol. 2012;30(35):4352–9.

    Article  CAS  PubMed  Google Scholar 

  34. Kohno T, Nakaoku T, Tsuta K, Tsuchihara K, Matsumoto S, Yoh K, et al. Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer. Transl Lung Cancer Res. 2015;4(2):156–64.

    CAS  PubMed  PubMed Central  Google Scholar 

  35. Vaishnavi A, Capelletti M, Le AT, Kako S, Butaney M, Ercan D, et al. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med. 2013;19(11):1469–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Fernandez-Cuesta L, Plenker D, Osada H, Sun R, Menon R, Leenders F, et al. CD74-NRG1 fusions in lung adenocarcinoma. Cancer Discov. 2014;4(4):415–22.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

    Sanja Dacic MD, PhD

Authors
  1. Sanja Dacic MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sanja Dacic MD, PhD .

Editor information

Editors and Affiliations

  1. Department of Pathology & Genomic Medici, Houston Methodist Hospital, Houston, Texas, USA

    Philip T. Cagle

  2. Department of Pathology, University of Texas Medical Branch, Galveston, Texas, USA

    Timothy Craig Allen

  3. Department of Pathology, Mount Sinai Medical Center, New York, New York, USA

    Mary Beth Beasley

  4. Department of Pathology, Brigham & Women’s Hospital, Boston, Massachusetts, USA

    Lucian R. Chirieac

  5. Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA

    Sanja Dacic

  6. Department of Pathology, Weill Cornell Medicine, New York, New York, USA

    Alain C. Borczuk

  7. Department of Pathology, Aberdeen University Medical School, Aberdeen, United Kingdom

    Keith M. Kerr

  8. Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA

    Lynette M. Sholl

  9. Medical Innovation, Roche Tissue Diagnostics, Ventana Medical Systems, Tucson, Arizona, USA

    Bryce Portier

  10. Cancer Center, Houston Methodist Hospital, Houston, Texas, USA

    Eric H. Bernicker

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Cite this chapter

Dacic, S. (2018). Translocation Testing of Lung Cancer Biomarkers. In: Cagle, P., et al. Precision Molecular Pathology of Lung Cancer. Molecular Pathology Library. Springer, Cham. https://doi.org/10.1007/978-3-319-62941-4_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-62941-4_8

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-62940-7

  • Online ISBN: 978-3-319-62941-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation